San Diego, CA, United States of America

Cheng-Yao Chen

This inventor holds 38 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Nucleic Acid Sequencing. Top assignees: Illumina Corporation, Life Technologies Corporation, University of California. Active years: 2014-2025.

USPTO Granted Patents = 38 

% Patents Active = 100.0


 

Average Co-Inventor Count = 5.5

ph-index = 11

Forward Citations = 329(Granted Patents)


Location History:

  • Carlsbad, CA (US) (2014 - 2017)
  • Eugene, OR (US) (2020 - 2022)
  • San Diego, CA (US) (2015 - 2023)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Nucleic Acid Synthesis
Polymerase Compositions
Single Molecule Sequencing
Conformational Probes
Nucleotide Binding
Energy Transfer Detection
Kinetic Analysis
Modified Polymerases
Sequencing Methods
Nucleotide Analogues
Blocking Groups
38 patents (USPTO):Explore Patents

Title: Cheng-Yao Chen: Innovator from San Diego

Introduction: Cheng-Yao Chen is a renowned inventor based in San Diego, CA, known for his groundbreaking contributions to various technological fields.

Latest Patents: Chen holds several patents in the areas of biotechnology, renewable energy, and artificial intelligence, showcasing his diverse range of expertise and innovation.

Career Highlights: With over two decades of experience in research and development, Chen has worked with leading tech companies and research institutions, consistently pushing the boundaries of innovation.

Collaborations: Throughout his career, Chen has collaborated with top scientists, engineers, and researchers globally, fostering a culture of innovation and knowledge exchange.

Conclusion: Cheng-Yao Chen's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and researchers worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…